logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

AACR 2018 — ARROW validates BLU-667 as promising therapy for RET-altered cancers

BLU-667 offers similar efficacy and better tolerability than older multikinase inhibitors.